Option chain shows key data for Applied DNA Sciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Applied DNA Sciences.

Applied DNA Sciences (NASDAQ:APDN) Stock, Option Chain

Applied DNA Sciences

Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.

dna-3539309

News

APDN

Applied DNA Sciences shares are trading higher by 18.7% during Tuesday&#39;s session. The company announced it positioned its TR8 PGx testing as pre-emptive testing for therapeutic safety.

Why Applied DNA Sciences (APDN) Stock Is Rising

Wall Street

Equities

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

Markets

Trading Ideas

CRVS

NUKK

PRZO

QUBT

U.S. stock futures climbed on Wednesday as Wall Street awaits the Fed&#39;s final interest rate decision and its monetary policy forecasts for 2025.

US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Earnings

AUID

CERO

COMM

EFSH

FSBW

NIVF

PRTG

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Applied DNA Sciences, Inc. - Common Stock

Applied DNA Sciences Inc

Press Releases

Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A  Laboratory-Developed Test

Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3

Applied DNA Reports Second Quarter Fiscal 2025 Financial Results

Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025

Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17

Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August

Management

Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward

HC Wainwright & Co.

Comments

Applied DNA Sciences

Applied DNA Sciences (APDN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell